Introduction {#S1}
============

Atrial fibrillation (AF), the most common clinical cardiac arrhythmia, has high morbidity, disability and mortality and has become a serious public health issue and socioeconomic burden worldwide ([@B8]; [@B36]). To date, the pathophysiological mechanisms of AF initiation and progression have not been completely elucidated. Emerging evidence indicates that autoimmunity mechanisms play an important role in the development of AF and might be a direct cause of and contributor to AF in some patients ([@B37]; [@B25]; [@B15]).

The beta 1-adrenergic receptor (β1AR) is a type of transmembrane receptor belonging to the cardiovascular G-protein-coupled receptor family. β1AR is the predominant β-adrenoceptor subtype in the human heart, accounting for 60--70% and 70--80% of β-adrenoceptors in the human atrium and ventricle, respectively ([@B39]). Early studies have confirmed that elevated levels of autoantibodies against β1AR (β1ARAbs) can induce cardiomyopathy and heart failure ([@B40]). Current evidence from both clinical studies and animal-model experiments has revealed that β1ARAb is also of pathogenic importance in AF. [@B44] found that serum β1ARAb levels were higher in patients with paroxysmal AF (PAF) than in healthy controls, and β1ARAb levels were an independent predictor of PAF occurrence. Furthermore, [@B17] demonstrated an ascending gradient of serum β1ARAb levels from healthy control subjects to PAF patients to patients with persistent AF. Additionally, the area under the curve of β1ARAb concentration predicted AF recurrence after cryoablation in patients with PAF ([@B45]). Evidence from experiments in a rabbit autoimmune model showed that animals developed high titers of β1ARAbs after immunization with the second extracellular loop (ECL2) peptide of β1AR, and elevated β1ARAbs reduced the atrial effective refractory period (AERP) and facilitated AF induction ([@B28], [@B26]). However, the underlying pathogenetic mechanisms of β1ARAb-mediated AF remains unclear.

Atrial fibrosis is one of the fundamental mechanisms of AF ([@B4]), and previous studies showed that β1ARAbs could induce cardiomyopathy by promoting ventricular fibrotic structural remodeling ([@B33]; [@B14]). Thus, we hypothesize that atrial fibrosis might be an important mechanism in β1ARAb-mediated AF. To this end, we measured the levels of β1ARAb in patients with PAF and analyzed their correlation with the presence of atrial fibrosis via non-invasive assessments that included echocardiographic LA diameter and circulating fibrosis biomarkers. Furthermore, we established a rabbit model by passive immunization against β1ARAbs; in this model, we examined whether increased expression of β1ARAbs plays a role in atrial fibrotic remodeling.

Materials and Methods {#S2}
=====================

Ethics Committee Approval {#S2.SS1}
-------------------------

The protocol for the clinical study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (Approval Number: 20170213-02) and conformed to the principles of the Declaration of Helsinki. All participants provided written informed consent for participation. The protocol for the experimental study was approved by the Institutional Animal Care and Use Committee of the First Affiliated Hospital of Xinjiang Medical University (Approval Number: IACUC-20170420-03) and conformed to the principles of the International Association of Veterinary Editors' Consensus Guidelines as well as the Basel Declaration. Anesthesia procedures were performed with pentobarbital sodium (30 mg/kg) via the marginal ear vein, and pentobarbital sodium was given as needed to maintain the depth of anesthesia during surgery. All efforts were made to minimize animal suffering.

Study Population and Data Collection {#S2.SS2}
------------------------------------

From July 2017 to March 2018, 70 consecutive patients who were newly diagnosed with PAF and were admitted to the Heart Center of the First Affiliated Hospital of Xinjiang Medical University were recruited. PAF was defined as AF episodes cardioverted within 7 days after onset, as stated by the 2016 European Society of Cardiology AF guidelines ([@B22]). Patients with autoimmune diseases, heart failure with reduced ejection fraction, history of acute coronary syndrome, severe valvular heart disease, or infectious diseases were excluded from our study. Participants underwent echocardiographic examination by experienced sonographers with a GE Vivid E9 ultrasound instrument (GE Vingmed Ultrasound, Horten, Norway). Information on demographic and clinical characteristics was obtained for all recruited patients.

Enzyme-Linked Immunosorbent Assay (ELISA) {#S2.SS3}
-----------------------------------------

A 5 mL peripheral vein blood sample from each patient was collected in a non-anticoagulant blood-collection tube in the morning after a 12 h fast. The blood was centrifuged at 3000 rpm for 10 min to obtain the serum, which was then stored at -80°C until processing. The serum levels of β1ARAb, procollagen type III N-terminal peptide (PIIINP), procollagen type I C-terminal peptide (PICP), and galectin-3 (Gal3) were measured quantitatively using ELISA kits according to the manufacturer's instructions. PIIINP, PICP and Gal3 were analyzed using kits produced by Elabscience (E-EL-H0183c, E-EL-H0196c, and E-EL-H1470c; Beijing, China), and the kit used to measure β1ARAbs was from Cusabio (CSB-E15079h; Wuhan, China).

Experimental Animals and Design {#S2.SS4}
-------------------------------

Sixteen male New Zealand white rabbits (each weighing 3.0--3.5 kg at baseline) were obtained from the Experimental Animal Center of Xinjiang Medical University (Urumqi, China) and were randomly divided into two groups: a control group and an immune group. The generation of the animal model followed the protocols of previous studies ([@B27], [@B28], [@B26]), and a flow chart of the experimental design is shown in [Figure 1A](#F1){ref-type="fig"}. The immune group was initially immunized with 2 mg of the β1AR ECL2 peptide (amino acid sequence: ^197^HWWRAESDEARRCYNDPKCCDFVTNR^223^; 98.13% purity, synthesized by Biosynthesis Biotechnology Inc., Beijing, China) in 1 mL of complete Freund's adjuvant (Sigma-Aldrich, St. Louis, MO, United States) at 0 weeks and was boosted with 2 mg of the β1AR ECL2 peptide and incomplete Freund's adjuvant (2 mg in 1 mL; Sigma-Aldrich, St. Louis, MO, United States) three times, spaced 2 week apart. Rabbits in the control group received an equal amount of adjuvant without the β1AR ECL2 peptide at the same time points. Blood samples were collected from both groups every 2 weeks in an awake state before injection, and the serum β1ARAb levels were measures by ELISA and expressed as optical density values based on previous studies ([@B28]). Transthoracic echocardiographic examination was performed at baseline and repeated at 8 weeks after the first immunization. Atrial electrophysiological studies, multielectrode array (MEA) measurement and histological analyses were performed at 8 weeks.

![Schematic of the study process. **(A)** study protocol diagram; **(B)** ELISA results (β1ARAb OD values) in the two groups. \**P* \< 0.05, control group vs. immune group at the same time point. ELISA, enzyme-linked immunosorbent assay; β1ARAb, beta 1-adrenergic receptor autoantibody; OD, optical density.](fphys-11-00076-g001){#F1}

Echocardiography {#S2.SS5}
----------------

Echocardiographic examinations of all rabbits were performed with a PHILIPS HD11XE transthoracic doppler ultrasound imaging system (Philips Inc., Bothell, WA, United States) with an S12-4 scan probe by an experienced sonographer who was blinded to the nature of the animal experiment. After the rabbits were anesthetized, the hair in the anterior chest area was shaved, the rabbits were placed in the left lateral decubitus position, and the measurements were taken. The left atrial diameter (LAD), right atrial diameter (RAD), left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD), right ventricular diameter (RVD), and left ventricular ejection fraction (LVEF) were measured. Each result was recorded as the average across three consecutive cardiac cycles.

Electrophysiological Measurement {#S2.SS6}
--------------------------------

Under anesthesia, surface electrocardiogram (ECG) leads were placed onto the extremities of the animals and connected to a computer-based multichannel physiological laboratory system (LEAD-7000, Jinjiang Electronic Science and Technology Inc., Chengdu, China) to record the heart rate for 5 min. Spontaneous arrhythmia episodes within 5 min were also documented. Then, the neck region was shaved, iodine disinfectant was applied, and an incision was made. The right jugular vein was isolated and intubated with a 4F sheath. The quadripolar electrode catheter entered the right atrium under the control of ECG, and the atrial potential was recorded in combination with surface ECG.

AERP and AF inducibility were measured as described in our previous study ([@B41]). AERP was conducted with a programmed train of eight basic stimuli (S1-S1 = 260 ms) followed by one extra stimulus (S2) with an initial pacing length of 200 ms and 5 ms decrements until S2 failed to capture the depolarization. The longest S1-S2 interval was defined as the AERP. The AERP was measured three times, and the average value was calculated. The inducibility of AF was assessed by burst pacing to the right atrium (twofold threshold current, cycle length 50 ms, duration 30 s per bout), and this treatment was repeated 5 times for each rabbit. AF inducibility was calculated as the percentage of successfully recorded AF. AF was defined as irregular, rapid atrial beats \> 500 beats per minute (bpm) for more than 1000 ms ([@B46]). Other types of arrhythmias induced in the rabbit were defined as follows: (1) atrial premature beat: a premature P wave that is morphologically a variant or replica of the P waves of the baseline rhythm; (2) sinus tachycardia: regular, rapid heart rate \> 250 bpm with 1:1 atrioventricular conduction arising from the sinus node; and (3) atrial flutter: regular, rapid atrial beats \> 250 bpm with distinct P waves between variable QRS cycles ([@B10]).

Flexible MEA Recording {#S2.SS7}
----------------------

MEA measurement was performed at sinus rhythm following electrophysiological study to record the conduction and conduction heterogeneity of the LA appendage epicardial surface *in vivo*. The chest of each rabbit was opened by cutting the center of the sternum, and the heart was exposed. A flexible MEA chip with 36 electrodes (6 × 6 electrodes, interelectrode distance: 300 μm, electrode diameter: 30 μm) was positioned at the surface of the LA appendage ([Supplementary Figure S1](#FS1){ref-type="supplementary-material"}). When the unipolar electrograms of the MEA recording were stable, recordings were taken to generate an activation map and calculate the conduction velocity (CV). The inhomogeneity index was calculated as a variation coefficient of CV (P~5--95~/P~50~) ([@B24]). Data were collected at 10 kHz per channel and analyzed with Cardio2D + software (Multi Channel Systems, Reutlingen, Germany).

Histological Collection and Processing {#S2.SS8}
--------------------------------------

The animals were sacrificed with high doses of pentobarbital sodium at the end of the experiment, and the hearts were quickly removed. The left atrial tissues were divided into small pieces, fixed in paraformaldehyde for histological staining, frozen in liquid nitrogen, and stored at −80°C for protein and mRNA analysis.

Atrial tissues were fixed in 4% paraformaldehyde for 24 h and then embedded in paraffin. The atrial tissue was sliced into 5 μm-thick cross-sections to visualize the cell structure. The sections were deparaffinized and subjected to hematoxylin and eosin (H&E) staining, Masson's trichrome staining, and picrosirius red staining for assessment of basic tissue structure and detection of fibrosis following the methods of our previous study ([@B41]). Digital photographs were taken under a Leica microscope (DM2500, Wetzlar, Germany). The distribution of collagen area was measured by two staining methods (Masson's trichrome staining and picrosirius red staining). The histopathological sections were analyzed using Image-Pro Plus software (version 6.0, Media Cybernetics, United States). The collagen area was calculated as the area of positive collagen staining divided by the entire myocardial area (%).

Western Blotting Analysis {#S2.SS9}
-------------------------

Western blot analysis was performed to detect the expression levels of transforming growth factor-β1 (TGF-β1), collagen I and collagen III; the protocols were as previously described ([@B41]). Briefly, 40μg of protein was fractionated by 12% SDS-PAGE and then transferred onto PVDF membranes. The membranes were blocked with 5% non-fat milk for 2 h and then incubated with primary antibodies overnight at 4°C. After being washed, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 2 h. Finally, the membranes were visualized with chemiluminescence reagents (EMD Millipore, Billerica, MA, United States). ImageJ 1.41 Software (NIH, Bethesda, MD, United States) was used to analyze the density of the Western blotting bands. The primary antibodies were as follows: anti-TGF-β1 (1:1000; Abcam, Cambridge, MA, United States), anti-collagen I (1:1000; Abcam, Cambridge, MA, United States) and anti-collagen III (1:1000; Bioss, Beijing, China) antibodies. All protein expression levels were normalized to the GAPDH expression level (1:1000; Goodhere Biotech, Hangzhou, China).

Real-Time Polymerase Chain Reaction (RT-PCR) {#S2.SS10}
--------------------------------------------

RT-PCR was used to quantitatively describe the mRNA expression of TGF-β1, collagen I and collagen III. Total RNA was extracted with TRIzol Reagent (Ambion, Austin, TX, United States) according to the manufacturer's instructions. RT-PCR was performed on an ABI QuantStudio 6 Flex RT-PCR System (Applied Biosystems, United States) with the SYBR Green I incorporation method. The relative expression levels of mRNAs were calculated using the 2^--ΔΔ*Ct*^ method. GAPDH was used as the internal control. The primers for related genes are listed in [Table 1](#T1){ref-type="table"}.

###### 

Primer sequences for RT-PCR.

  Genes          Forward                          Reverse
  -------------- -------------------------------- ------------------------------
  TGF-β1         5′-AGCTGTACATTGACTTCCGCAAGG-3′   5′-CAGGCAGAAGTTGGCGTGGTAG-3′
  Collagen I     5′-AACTTGCCTTCATGCGTCTG-3′       5′-CCTCGGCAACAAGTTCAACA-3′
  Collagen III   5′-CGGACTTGCAGGAATTACAGG-3′      5′-TTTCCGTCTCTTCCAGGTTCA-3′
  GADPH          5′-CAGGGCTGCTTTTAACTCTGG-3′      5′-TGGAAGATGGTGATGGCCTT-3′

RT-PCR, reverse transcription polymerase chain reaction; TGF-β1, transforming growth factor-beta 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Statistical Analysis {#S2.SS11}
--------------------

Data analysis was performed using SPSS software (version 23.0, SPSS Inc., Chicago, IL, United States). Continuous data are presented as the means and standard deviations and were evaluated by Student's *t*-test. Classification data were presented as proportions and evaluated by the chi-squared test or Fisher's exact test. Correlations between β1ARAb levels and other parameters were ascertained by Pearson's correlation coefficient or Spearman's rank correlation coefficient. A two-tailed *P* \< 0.05 was considered statistically significant.

Results {#S3}
=======

Clinical Characteristics of the Study Population {#S3.SS1}
------------------------------------------------

This study enrolled 70 patients with PAF; their baseline clinical characteristics are described in [Table 2](#T2){ref-type="table"}. According to LA anteroposterior diameter, participants were divided into two groups: a group with LA diameter \< 40 mm (*n* = 47) and a group with LA diameter ≥ 40 mm (*n* = 23). Patients with atrial enlargement had a higher level of β1ARAbs (8.87 ± 3.16 vs. 6.75 ± 1.34 ng/mL, *P* = 0.005) and a lower LVEF (60.21 ± 4.87 vs. 62.95 ± 5.47%, *P* = 0.045) than those without atrial enlargement. No differences in age, sex, comorbidity, blood biochemical parameters or fibrosis-related biomarkers were observed between the two groups (all *P* \> 0.05).

###### 

The clinical characteristics of the study population.

  Characteristics                 Total participants (*n* = 70)   LA anteroposterior diameter   *P*-value       
  ------------------------------- ------------------------------- ----------------------------- --------------- -------
  Age, years                      60.57 ± 13.25                   60.17 ± 13.47                 61.39 ± 13.04   0.720
  Male, n (%)                     39 (55.7)                       27 (57.4)                     12 (52.2)       0.677
  Hypertension, n (%)             33 (47.1)                       21 (44.7)                     12 (52.2)       0.555
  Diabetes mellitus, n (%)        15 (21.4)                       10 (21.3)                     5 (21.7)        0.965
  Coronary heart disease, n (%)   12 (17.1)                       8 (17.0)                      4 (17.4)        0.969
  History of stroke, n (%)        14 (20.0)                       7 (14.9)                      7 (30.4)        0.127
  CHA~2~DS~2~-VASc score          2.19 ± 1.84                     2.09 ± 1.78                   2.39 ± 1.99     0.518
  HAS-BLED score                  1.01 ± 1.07                     0.94 ± 0.99                   1.17 ± 1.23     0.386
  LVEF, %                         62.05 ± 5.40                    62.95 ± 5.47                  60.21 ± 4.87    0.045
  ALT, U/L                        20.00 ± 5.46                    19.75 ± 5.60                  20.52 ± 5.25    0.583
  FBG, mmol/L                     5.13 ± 0.82                     4.97 ± 0.59                   5.44 ± 1.12     0.069
  TG, mmol/L                      1.59 ± 1.01                     1.68 ± 1.14                   1.39 ± 0.63     0.168
  TC, mmol/L                      3.76 ± 0.96                     3.78 ± 0.88                   3.73 ± 1.12     0.855
  LDLC, mmol/L                    2.35 ± 0.78                     2.33 ± 0.76                   2.40 ± 0.85     0.745
  HDLC, mmol/L                    1.11 ± 0.31                     1.13 ± 0.33                   1.09 ± 0.27     0.602
  β1ARAbs, ng/mL                  7.45 ± 2.33                     6.75 ± 1.34                   8.87 ± 3.16     0.005
  PIIINP, ng/mL                   17.09 ± 6.30                    16.17 ± 4.72                  18.96 ± 8.51    0.081
  PICP, ng/mL                     4.10 ± 0.81                     4.03 ± 0.61                   4.26 ± 1.11     0.254
  Gal3, ng/mL                     2.02 ± 0.34                     1.96 ± 0.29                   2.13 ± 0.40     0.058

Values are presented as the mean ± SD, or n (%). LA, left atrial; LVEF, left ventricular ejection fraction; ALT, alanine transferase; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; LDLC, low-density lipoprotein cholesterol; HDLC, high-density lipoprotein cholesterol; β1ARAbs, beta 1-adrenergic receptor autoantibodies; PIIINP, procollagen type β N-terminal peptide; PICP, procollagen type C-terminal peptide; Gal3, galectin-3.

Correlation of β1ARAb Levels With Fibrosis and Clinical Indexes {#S3.SS2}
---------------------------------------------------------------

As demonstrated in [Figure 2](#F2){ref-type="fig"}, Pearson's linear correlation analysis showed that the serum β1ARAb levels were positively correlated with LA diameter and circulating biomarkers (LA diameter: *r* = 0.272, *P* = 0.023; PIIINP: *r* = 0.694, *P* \< 0.001; PICP: *r* = 0.316, *P* = 0.008; Gal3: *r* = 0.545, *P* \< 0.001). β1ARAb levels did not correlate significantly with other clinical indexes, including age, LVEF, hypertension, diabetes mellitus, coronary heart disease, history of stroke, CHA~2~DS~2~-VASc score and HAS-BLED score ([Table 3](#T3){ref-type="table"}).

![Correlation of serum β1ARAb levels with echocardiographic indexes and fibrosis-related biomarkers (**A**, PIIINP; **B**, PICP; **C**, Gal3; **D**, LA diameter). β1ARAb, beta 1-adrenergic receptor autoantibody; PIIINP, procollagen type III N-terminal peptide; PICP, procollagen type I C-terminal peptide; Gal3, galectin-3; LA, left atrial.](fphys-11-00076-g002){#F2}

###### 

Correlation analysis between β1ARAb levels and clinical indexes in patients with PAF.

                           *r*       *P*-value
  ------------------------ --------- -----------
  Age                      --0.009   0.939
  LVEF                     --0.108   0.374
  Hypertension             --0.070   0.564
  Diabetes mellitus        --0.187   0.121
  Coronary heart disease   0.024     0.841
  History of stroke        0.140     0.249
  CHA~2~DS~2~-VASc         --0.140   0.248
  HAS-BLED                 --0.021   0.861

β1ARAb, beta 1-adrenergic receptor autoantibody; LVEF, left ventricular ejection fraction.

Effect of β1ARAbs on Atrial Electrophysiology {#S3.SS3}
---------------------------------------------

All rabbits in both groups survived through the entire research period. From the second week onward, the rabbits in the immune group, immunized with the β1AR ECL2 peptide, developed higher levels of β1ARAb than the control group ([Figure 1B](#F1){ref-type="fig"}).

Spontaneous AF episodes were observed in two rabbits in the immune group in the observational period prior to the invasive electrophysiological study, but the rate difference between groups was not statistically significant (2/8 vs. 0/8, *P* \> 0.05). Compared with the control group, the immune group showed a significantly increased heart rate (207.13 ± 8.63 vs. 177.13 ± 6.17 bpm, *P* \< 0.001), shortened AERP (70.00 ± 5.49 vs. 96.46 ± 3.27 ms, *P* \< 0.001), and increased rate of induced AF (55% vs. 0%, *P* \< 0.001) 8 weeks after immunization ([Figure 3](#F3){ref-type="fig"}).

![Electrophysiology measurements of the two groups. Comparison of heart rate **(A)**, AERP **(B)**, and AF inducibility **(C)** between the two groups; spontaneous APBs **(D)** and AF **(E)** observed in the immune group; representative sinus rhythm **(F)**, sinus tachycardia **(G)**, AFL episode **(H)** and AF episode **(I)** induced after burst pacing. \**P* \< 0.05, control group vs. immune group. AERP, atrial effective refractory period; AF, atrial fibrillation; APB, atrial premature beat; AFL, atrial flutter.](fphys-11-00076-g003){#F3}

[Figures 4A--C](#F4){ref-type="fig"} demonstrate the conduction activation maps and CV maps of the LA appendage epicardial surface; a slower CV (34.38 ± 8.48 vs. 61.50 ± 13.40 cm/s, *P* \< 0.001, [Figures 4D,E](#F4){ref-type="fig"}) and greater conduction inhomogeneity index (2.63 ± 0.40 vs. 1.52 ± 0.25, *P* \< 0.001, [Figures 4D,F](#F4){ref-type="fig"}) were observed in the immune group than in the control group.

![β1ARAbs reduced the LA conduction function. **(A)** Representative color maps of epicardial multielectrode activation in LA appendage; areas of isochronal crowding were found in rabbits of immune group; **(B)** representative examples of conduction heterogeneity map in LA appendage; **(C)** recording propagation map during sinus rhythm; **(D)** conduction maps of activation in LA appendage; β1ARAbs reduced CV **(E)** and increased conduction heterogeneity **(F)**. \**P* \< 0.05, control group vs. immune group. β1ARAbs, beta 1-adrenergic receptor autoantibodies; LA, left atrial; CV, conduction velocity.](fphys-11-00076-g004){#F4}

Changes in Echocardiography Parameters {#S3.SS4}
--------------------------------------

[Table 4](#T4){ref-type="table"} and [Figure 5A](#F5){ref-type="fig"} show echocardiographic changes. In the immune group, increases in LAD, RAD, LVEDD, and LVESD and a decrease in LVEF were observed compared with the baseline levels. Compared to the control group, the immune group had significant increases in LAD, LVEDD, and LVESD and a significant decrease in LVEF after 8 weeks. There were no significant differences in LAD, RAD, LVESD, RVD, or LVEF between the baseline and endpoint in the control group, although LVEDD slightly increased after 8 weeks.

###### 

Echocardiographic differences between the two groups.

  Parameters   Control group   Immune group                                           
  ------------ --------------- -------------- ------- -------------- ---------------- ----------
  LAD, mm      9.53 ± 0.43     9.77 ± 0.82    0.211   9.13 ± 0.64    10.93 ± 0.99\*   0.012
  RAD, mm      9.63 ± 0.71     10.53 ± 1.22   0.081   9.40 ± 1.11    11.23 ± 0.96     0.004
  LVEDD, mm    15.18 ± 0.83    16.05 ± 0.89   0.047   14.56 ± 0.97   16.89 ± 0.44\*   0.001
  LVESD, mm    10.67 ± 0.86    11.42 ± 1.08   0.158   9.99 ± 0.97    12.94 ± 1.02\*   \< 0.001
  RVD, mm      8.33 ± 0.59     8.55 ± 0.62    0.153   8.16 ± 0.62    8.61 ± 0.34      0.054
  LVEF, %      65.12 ± 5.14    63.71 ± 6.82   0.682   67.43 ± 5.77   54.47 ± 9.68\*   0.001

\*P \< 0.05 compared with the control group at the same time point. LAD, left atrial diameter; RAD, right atrial diameter; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; RVD, right ventricular diameter; LVEF, left ventricular ejection fraction.

![Schematic diagram of echocardiography results and histopathological changes in atrial tissues. **(A)** increased LAD and reduced cardiac function in the immune group; **(B)** representative images of H&E staining (40×); **(C)** angiogenesis (a, 20×), inflammatory cell infiltration (b, 40×), interstitial fibrosis (c, 40×) and increased ECM (d, 40×) in the left atrium of the immune group; **(D)** representative images of picrosirius red staining (40×) and Masson's trichrome staining (20×); **(E)** quantitative assessment of atrial fibrosis between two groups; **(F)** correlation of β1ARAb OD values of 8 weeks with total collagen area. \**P* \< 0.05, control group vs. immune group. LAD, left atrial diameter; H&E, hematoxylin and eosin; ECM, extracellular matrix; β1ARAb, beta 1-adrenergic receptor autoantibody; OD, optical density.](fphys-11-00076-g005){#F5}

Histopathological Changes {#S3.SS5}
-------------------------

In the control group, H&E staining showed that the cardiomyocytes were arranged neatly, and there was a small amount of connective tissue in the extracellular matrix (ECM, [Figure 5B](#F5){ref-type="fig"}). However, the interstitial structure was disordered in the immune group, with extensive fibrous tissue hyperplasia accompanied by inflammatory cell infiltration and increased angiogenesis ([Figure 5C](#F5){ref-type="fig"}).

Additionally, increased collagen accumulation in the ECM in the immune group was observed by Masson's trichrome staining (15.17 ± 3.46 vs. 4.92 ± 1.72%, immune and control groups, respectively, *P* \< 0.001) and picrosirius red staining (16.76 ± 6.40 vs. 4.85 ± 0.40%, immune and control groups, respectively, *P* \< 0.001, [Figures 5D,E](#F5){ref-type="fig"}). Correlation analysis showed a significant positive correlation between circulating β1ARAb levels at 8 weeks and total fiber area (*r* = 0.895 and 0.786 for Masson's trichrome staining and picrosirius red stain, respectively, both *P* \< 0.001, [Figure 5F](#F5){ref-type="fig"}).

Fibrosis-Related Protein and Gene Expression {#S3.SS6}
--------------------------------------------

As shown in [Figure 6](#F6){ref-type="fig"}, the messenger RNA and protein expression levels of TGF-β1, collagen I and collagen III were significantly upregulated in the immune group compared with the control group.

![Expression levels of TGF-β1, collagen I and collagen III in atrial tissues. **(A)** Western blotting results for TGF-β1, collagen I and collagen III in the two groups. Relative protein and mRNA expression of TGF-β1 **(B)**, collagen I **(C)**, and collagen III **(D)** are shown, following normalization to GAPDH. \**P* \< 0.05, control group vs. immune group. TGF-β1, transforming growth factor-β1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.](fphys-11-00076-g006){#F6}

Discussion {#S4}
==========

Main Finding {#S4.SS1}
------------

In the present study, we analyzed the relationship between β1ARAbs and non-invasive atrial fibrosis indicators in patients with PAF and examined the effects of atrial structural remodeling in a rabbit model with enhanced β1ARAbs expression. The major findings were as follows: (1) β1ARAb levels were positively correlated with LA anterior-posterior diameter and three circulating fibrosis markers (PIIINP, PICP, Gal3) in PAF patients; (2) excessive expression of β1ARAbs increased LAD and interstitial fibrosis and led to increased inducibility of AF along with shortened AERP, slowed CV and increased conduction heterogeneity.

β1ARAbs in AF Patients {#S4.SS2}
----------------------

Fibrosis is an important part of atrial remodeling in AF, and an increased LA diameter is a simple indicator of severe atrial structural remodeling and interstitial fibrosis or scarring ([@B29]). In addition, left atrium enlargement is the pathological basis and a major determinant of AF and its progression. Our study reported for the first time that β1ARAb levels have a positive linear correlation with LA diameter but are not associated with other clinical manifestations or comorbidities, suggesting that β1ARAbs may cause atrial structural remodeling and might be involved in the development of AF. This result supports the previous observation that patients with persistent AF have higher β1ARAb levels than patients with PAF ([@B17]). At the same time, our finding might also partly explain why elevated β1ARAb levels increased the AF recurrence rate after cryoablation in a previous study ([@B45]), as enlarged LA size is a well-known, consistent, independent predictor of recurrence following ablation in AF; its predictive ability has been confirmed in large observational studies and meta-analyses ([@B48]; [@B21]). Furthermore, [@B12] found that in hypertrophic cardiomyopathy patients, those with LA diameters ≥ 50 mm had significantly higher levels of β1ARAbs than those with smaller LA diameters \[52.78 (46.76, 58.34) vs. 45.03 (36.74, 55.44) ng/mL, *P* = 0.042\]. Our result was similar to that of a recently published study investigating the association of another G-protein-coupled receptor autoantibody (against the M2-muscarinic acetylcholine receptor) with atrial fibrosis in AF patients; a positive correlation was found between serum autoantibody levels and collagen volume in LA appendages ([@B32]).

The main feature of atrial fibrosis is increased collagen deposition in the ECM, and human atrial fibrosis is mainly composed of types I and III collagen ([@B3]). In the process of atrial fibrosis development, components for collagen synthesis, secretion, renewal, and deposition, such as PICP and PIIINP, are released into the blood and can be used as circulating biomarkers ([@B11]). Gal3, a member of the galectin family, is elevated in fibrotic conditions and highly expressed in fibrotic cardiac tissues ([@B5]; [@B9]). In our study, serum β1ARAb levels were correlated with the levels of three fibrosis-related biomarkers. To date, however, there have been conflicting results regarding the predictive value of circulating biomarkers in atrial fibrosis. Data from patients undergoing cardiac surgery demonstrated that serum PICP levels correlated significantly with the percentage of LA fibrosis from atrial biopsy specimens ([@B38]). Nevertheless, other studies failed to verify the correlation between these biomarkers and fibrosis as assessed by LA low-voltage area ([@B1]). A convincing explanation is that the blood levels of fibrosis-related biomarkers are susceptible to non-cardiac fibrosis, and systemic fibrosis masks their peripheral levels ([@B2]). In our study, we pre-excluded patients with severe heart failure and those with autoimmune or infectious diseases; only patients newly diagnosed with PAF were included. We hoped that, once diseases which could cause non-atrial fibrosis were mainly eliminated, the levels of these biomarkers could indicate the severity of atrial fibrosis. In addition, our results showed only weak to moderate correlations between β1ARAb levels and non-invasive atrial fibrosis indexes, although the correlations were statistically significant. The clinical significance must be interpreted with caution.

Elevated β1ARAbs Increase AF Susceptibility in an Animal Model {#S4.SS3}
--------------------------------------------------------------

We observed spontaneous AF in two immunized rabbits, although the intergroup difference in proportion was not statistically significant (2/8 vs. 0/8). Nonetheless, this finding suggested that elevated β1ARAbs might be a direct cause of AF. We also evaluated the AF propensity of these animals, and the results showed that the heart rate was enhanced and AERP was shortened after immunization, which was similar to the results of a previous study ([@B28]). However, we observed a much higher rate of induced AF (22/40) than reported in that previous study (1/24), probably because we used a higher dose of injected β1ARAbs and a longer modeling time in our study. These results suggest that β1ARAbs and AF may have a dose-response relationship, as previous studies have also shown a significant negative correlation between β1ARAb levels and AERP ([@B28]).

β1ARAbs Promote Atrial Structural Remodeling and Related Mechanisms {#S4.SS4}
-------------------------------------------------------------------

Previous studies have fully demonstrated that the long-term overexpression of β1ARAbs can cause ventricular structural changes and contribute to cardiomyopathy and heart failure progression ([@B18]; [@B49]). Our results were consistent with those of previous studies and generally corresponded to the expected results, with LVEDD and LVESD being increased and LVEF being decreased in the immune group after 8 weeks. In this present study, we focused on the structural changes in the atrium, and we found that overexpression of β1ARAbs led to atrial structural remodeling, manifested by increased LA diameter, heavy collagen deposition in the ECM, and increased protein and mRNA expression of collagen I and III, indicating that the heart damage caused by β1ARAbs includes both atrial and ventricular damage. This result was also consistent with the reduction in CV and the increase in conduction heterogeneity in the immune group on MEA recording, as extensive atrial fibrosis leads to disturbances in electrical conduction, and fibrous scars impede the normal conduction of atrial myocytes. Previous studies have verified that β1ARAbs specifically bind to β1ARs and exhibit agonistic activity against them, resulting in myocardial damage and cardiac dysfunction ([@B42]). Since β1AR is one of the predominant adrenergic receptors widely distributed throughout the myocardial tissue, this might explain why β1ARAbs also damage the atrium. Our results were similar to those of a previous study in an autoimmune myocarditis rat model, in which researchers found that the inducibility of AF was dependent on atrial structural remodeling rather than inflammation ([@B16]).

Our study did not delve into the mechanism-based signaling pathways that regulate β1ARAb-mediated atrial fibrosis. However, numerous studies have shown that at the cellular and molecular levels, various cardiac damage and pathogenic factors cause atrial fibrosis through the shared mechanism of fibroproliferative signaling, and TGF-β1 is a key mediator of ECM protein expression and fibrosis ([@B30]). In our models, the protein and mRNA expression levels of TGF-β1 were significantly elevated, indicating that the TGF-β1 signaling pathway is activated in the β1ARAb overexpression model. A previous study found that β1ARAbs activated the β1AR/cAMP/PKA pathway and promoted the proliferation and activation of cardiac fibroblasts ([@B31]). Activated cardiac fibroblasts are characterized by increased synthesis of collagen I and III and increased deposition of those proteins in the ECM ([@B6]). In addition, many cytokines, such as IL-6 and TGF-β1, are secreted by fibroblasts in response to stimulation by pathogenic factors ([@B13]; [@B6]). More interestingly, TGF-β1 can modulate cardiomyocyte survival and activate fibroblasts ([@B47]). Therefore, we speculated that active cardiac fibroblasts and TGF-β1 could promote each other, forming a positive feedback loop that promotes β1ARAb-induced atrial fibrosis and AF propensity, but further verification is needed. In addition, previous research also confirmed that β1ARAb activated the canonical cAMP/PKA signaling pathway in cardiomyocytes, leading to functional alterations in intracellular calcium handling ([@B20]). Sustained β1ARAb agonism eventually elicited caspase-3 activation and promoted cardiomyocyte apoptosis *in vivo* ([@B20]).

Therapeutic Implications of β1ARAb-Mediated AF {#S4.SS5}
----------------------------------------------

Evidence from clinical and experimental studies illustrates that immunoadsorption of circulating β1ARAbs improved cardiac function in cardiomyopathy ([@B34]; [@B35]). However, immunoadsorption therapy has the shortcomings of high cost, logistical challenges, and considerable time and labor requirements; oral drug treatment is increasingly coming to the fore ([@B19]; [@B43]). Since β1ARAbs produce downstream effects by stimulating cardiac β1ARs, β-adrenoceptor inhibitors might be an effective treatment for β1ARAb-mediated injury. Evidence from an experimental study showed that nebivolol attenuates TGF-β1 pathways in a renovascular hypertension disease model ([@B7]). Further studies are needed to determine whether β-adrenoceptor blockers have beneficial antifibrotic effects in a β1ARAb overexpression model.

Limitations {#S4.SS6}
-----------

Our study has several limitations that should be mentioned. First, the cross-sectional study design did not allow us to address the causal relationship between β1ARAb levels and atrial fibrosis in PAF patients, however, we compensated by performing animal experiments. Second, we did not apply more-accurate methods to evaluate the severity of atrial fibrosis, such as cardiac magnetic resonance imaging, electrophysiological mapping, or atrial tissue biopsy. Therefore, further larger-sample cohort studies of healthy controls and different types of AF patients are necessary to demonstrate the clinical significance of β1ARAbs in AF patients. Our experiment did not include groups with different concentrations of β1ARAbs, meaning that it could not address the dose-response relationship between β1ARAbs and AF. Numerous effectors and mechanisms, such as inflammatory reactions and cardiomyocyte apoptosis, are involved in the progression of cardiac fibrosis ([@B23]); whether these mechanisms are involved in β1ARAb-induced atrial fibrosis remains unclear and needs to be addressed in further research. Additionally, our study lacks pharmacological data; therefore, the results cannot be directly used in clinical practice.

Conclusion {#S5}
==========

In conclusion, β1ARAb levels are positively correlated with LAD and circulating fibrosis-related biomarkers in patients with PAF. β1ARAb overexpression increases AF inducibility by facilitating atrial fibrosis, TGF-β1 signaling activation and collagen accumulation. Our results suggest that reversing atrial fibrosis may be a potential therapeutic target for the upstream prevention of β1ARAb-mediated AF.
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AERP

:   atrial effective refractory period

AF

:   atrial fibrillation

β 1AR

:   beta 1-adrenergic receptor

β 1ARAb

:   beta 1-adrenergic receptor autoantibody

CV

:   conduction velocity

ECG

:   electrocardiogram

ECL2

:   second extracellular loop

ECM

:   extracellular matrix

ELISA

:   enzyme-linked immunosorbent assay

Gal3

:   galectin-3

H&E

:   hematoxylin and eosin

LA

:   left atrial

LAD

:   left atrial diameter

LVEDD

:   left ventricular end-diastolic dimension

LVEF

:   left ventricular ejection fraction

LVESD

:   left ventricular end-systolic dimension

MEA

:   multielectrode array

PAF

:   paroxysmal atrial fibrillation

PIIINP

:   procollagen type III N-terminal peptide

PICP

:   procollagen type I C-terminal peptide

RAD

:   right atrial diameter

RT-PCR

:   real-time polymerase chain reaction

RVD

:   right ventricular diameter

TGF- β 1

:   transforming growth factor- β 1.
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